Heightened ability of monocytes from sarcoidosis patients to form multi-nucleated giant cells in vitro by supernatants of concanavalin A-stimulated mononuclear cells.
The main immunocompetent cells in sarcoidal lesions are epithelioid cells and multi-nucleated giant cells (MGC), both of which are derived from monocyte-macrophage lineage cells. To understand further the relevance of monocytes in sarcoidosis, we examined in vitro MGC formation using monocytes from sarcoidosis patients, patients with other granulomatous diseases (OGD) and healthy control subjects. The supernatant of concanavalin A-stimulated peripheral blood mononuclear cells (conditioned medium) generated Langhans type-MGC and foreign body type-MGC from monocytes. Conditioned medium from any three groups had the same ability to form MGC from normal monocytes. On the other hand, MGC were more highly formed using monocytes from sarcoidosis patients than from other groups. When macrophages induced by treatment of monocytes with macrophage colony-stimulating factor (M-CSF) were used, the rate of MGC formation in sarcoidosis patients was about threefold or fourfold as much as that in OGD patients or healthy controls, respectively. Oxidized ATP inhibited MGC formation in all groups. The susceptibility of monocytes cultured in conditioned medium for 24 h to 2'- and 3'-o-(4-benzoyl-benzoyl)ATP-mediated cytolysis was significantly higher in sarcoidosis patients than other groups. These findings suggest that the ability of monocytes to form MGC through P2x7 receptors is enhanced in sarcoidosis patients.
Mizuno
K
K
Department of Dermatology, Kansai Medical University, Moriguchi, Osaka, Japan.
Okamoto
H
H
Horio
T
T
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D000328:Adult; D000368:Aged; D002459:Cell Fusion; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology*; D017077:Culture Media, Conditioned; D005260:Female; D015726:Giant Cells / Q000166:cytology*; D006801:Humans; D008264:Macrophages / Q000166:cytology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D018102:Receptors, Leukotriene B4; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D012507:Sarcoidosis / Q000209:etiology* / Q000473:pathology
D017077:Culture Media, Conditioned; C513240:LTB4R protein, human; D018102:Receptors, Leukotriene B4; D018048:Receptors, Purinergic P2; D003208:Concanavalin A; C033901:3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate; D000255:Adenosine Triphosphate